# Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke

> **NCT03735277** · PHASE1 · UNKNOWN · sponsor: **BHI Therapeutic Sciences** · enrollment: 10 (estimated)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **BIOLOGICAL:** HPC, Cord Blood

## Key facts

- **NCT ID:** NCT03735277
- **Lead sponsor:** BHI Therapeutic Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-06
- **Primary completion:** 2022-07
- **Final completion:** 2022-07
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2020-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03735277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03735277, "Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03735277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*